I think the ADDUCE study is worth examining for the question.
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study - PubMed
- This was a 2-year study of 1400 kids in Europe divided into three groups: 1. ADHD treated w/ Methylphenidate, 2. ADHD w/o Methylphenidate, and 3. No ADHD control.
- All three groups had a reduction of tics over the length of the study
- at the 6-month mark, there was no difference in the reduction of tics between the methylphenidate and the no methylphenidate groups
- at the 12-month mark, the reduction was greater in the no methylphenidate group (statistically significant)
- At the 24-month mark, the no methylphenidate group (~ 400 kids) rate was zero; the methylphenidate group was 2.4.
My takeaway is that, as
@calvnandhobbs68 noted, this is a period of high activity for the life cycle of tics. However, given that there is a difference over time between the groups, it is also not unreasonable to look at the individual patient and consider that a stimulant might be contributing to their specific presentation.